<

Effect of enoxaparin sodium on pregnant women.

    Enoxaparin sodium, also known as heparin, is a treatment and prevention of deep vein thrombosis, unstable angina, pulmonary embolism and other diseases. Pregnant women are a special group, especially in the use of drugs, must not be at will, need to know in the doctor's medication, otherwise it will affect the normal development of children. So can pregnant women use enoxaparin sodium? Below will carry on the detailed introduction for everybody!

Effect of enoxaparin sodium on pregnant women.

  One, indication

  Prevention of venous thromboembolic diseases (prevention of venous thrombosis), especially those related to orthopaedic or general surgery.

  Treatment of established deep vein embolism, with or without pulmonary embolism, with mild clinical symptoms, and does not include pulmonary embolism requiring surgery or thrombolytic therapy.

  For the treatment of unstable angina pectoris and non-Q-wave myocardial infarction, use in combination with aspirin.

  Used for hemodialysis in extracorporeal circulation to prevent thrombosis.

  Ii. Usage and Dosage:

  During the treatment of deep vein thrombosis:

  Enoxaparin should be replaced with oral anticoagulant therapy as soon as possible unless contraindicated. Enoxaparin treatment should not exceed 10 days, including the time required to achieve the effect of oral anticoagulant therapy, unless the goal is not achieved (see section 4.4 Precautions for use: platelet monitoring). Therefore, oral anticoagulants should be used as soon as possible.

  Treatment of unstable angina and non-Q-wave myocardial infarction:

  The recommended dose of enoxaparin for subcutaneous injection is 100

  AxaIU/kg, administered every 12 hours, should be used with aspirin (recommended dose: 160mg minimum load followed by 75 to 325 mg oral daily for 2 to 8 days until clinical symptoms stabilize. For cardiopulmonary bypass on hemodialysis to prevent thrombosis: the recommended dose is 100Axa IU/kg. For hemodialysis patients with high bleeding tendency, the dosage should be reduced, i.e. bilateral vascular access to enoxheparin 50Axa IU/kg or unilateral vascular access to enoxheparin 75Axa IU/kg. Enoxaparin sodium should be given in the arterial vascular access at the beginning of hemodialysis. The duration of action is usually 4 hours. However, when fibrin rings are present, an additional dose of 50 to 100 AxaIU/kg should be given.